{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T09:40:09Z","timestamp":1748770809168,"version":"3.41.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"DOI":"10.7759\/cureus.85173","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T09:09:00Z","timestamp":1748768940000},"source":"Crossref","is-referenced-by-count":0,"title":["Paediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Case Report With Varied Clinical Manifestations"],"prefix":"10.7759","author":[{"given":"Nur Ain","family":"Mohamad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safinaz","family":"Mohd Khialdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Shahirah","family":"Amir Hamzah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","unstructured":"Banwell B. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023, 22:268-82. 10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-044452763-9\/50076-7","article-title":"Anti-MOG antibodies","author":"Wurster U","year":"2007","unstructured":"Wurster U, Lindert RB, Torens I, Heidenreich F. Anti-MOG antibodies. Autoantibodies (Second Edition). Shoenfeld Y, Gershwin ME, Meroni PL (ed): Elsevier, Amsterdam; 2007. 591-8. 10.1016\/B978-044452763-9\/50076-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Corbali O","year":"2023","unstructured":"Corbali O, Chitnis T. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front Neurol. 2023, 14:1137998. 10.3389\/fneur.2023.1137998","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297923040107","article-title":"Myelin oligodendrocyte glycoprotein as an autoantigen in inflammatory demyelinating diseases of the central nervous system","volume":"88","author":"Eliseeva DD","year":"2023","unstructured":"Eliseeva DD, Zakharova MN. Myelin oligodendrocyte glycoprotein as an autoantigen in inflammatory demyelinating diseases of the central nervous system. Biochemistry (Mosc). 2023, 88:551-63. 10.1134\/S0006297923040107","journal-title":"Biochemistry (Mosc)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1559-8","article-title":"Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen","volume":"132","author":"Kinzel S","year":"2016","unstructured":"Kinzel S, Lehmann-Horn K, Torke S, et al.. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol. 2016, 132:43-58. 10.1007\/s00401-016-1559-8","journal-title":"Acta Neuropathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413174200","article-title":"Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis","volume":"280","author":"Marta CB","year":"2005","unstructured":"Marta CB, Montano MB, Taylor CM, Taylor AL, Bansal R, Pfeiffer SE. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis. J Biol Chem. 2005, 280:8985-93. 10.1074\/jbc.M413174200","journal-title":"J Biol Chem"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol CL","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, et al.. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020, 26:806-14. 10.1177\/1352458519845112","journal-title":"Mult Scler"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor JY","year":"2023","unstructured":"Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol. 2023, 14:1260358. 10.3389\/fneur.2023.1260358","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231156736","article-title":"Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey","volume":"29","author":"Nakamura M","year":"2023","unstructured":"Nakamura M, Ogawa R, Fujimori J, et al.. Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Mult Scler. 2023, 29:530-9. 10.1177\/13524585231156736","journal-title":"Mult Scler"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12479","article-title":"Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore\u2014epidemiology and evolution of an emerging subspecialty","volume":"9","author":"Tan K","year":"2021","unstructured":"Tan K. Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore\u2014epidemiology and evolution of an emerging subspecialty. Neurol Clin Neurosci. 2021, 9:259-65. 10.1111\/ncn3.12479","journal-title":"Neurol Clin Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104168","article-title":"The prevalence, demographics, clinical features, neuroimaging, and inter-ethnic differences of MOGAD in Malaysia with global perspectives","volume":"67","author":"Ong ZM","year":"2022","unstructured":"Ong ZM, Arip M, Ching YM, et al.. The prevalence, demographics, clinical features, neuroimaging, and inter-ethnic differences of MOGAD in Malaysia with global perspectives. Mult Scler Relat Disord. 2022, 67:104168. 10.1016\/j.msard.2022.104168","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51759","article-title":"Attack phenotypes and disease course in pediatric MOGAD","volume":"10","author":"Santoro JD","year":"2023","unstructured":"Santoro JD, Beukelman T, Hemingway C, Hokkanen SR, Tennigkeit F, Chitnis T. Attack phenotypes and disease course in pediatric MOGAD. Ann Clin Transl Neurol. 2023, 10:672-85. 10.1002\/acn3.51759","journal-title":"Ann Clin Transl Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162647","article-title":"Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases","volume":"14","author":"Li X","year":"2023","unstructured":"Li X, Wu W, Hou C, et al.. Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases. Front Immunol. 2023, 14:1162647. 10.3389\/fimmu.2023.1162647","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578083","article-title":"Paediatric MOG-antibody disease presenting with intracranial hypertension and unilateral vision loss without radiological evidence of optic neuritis","volume":"378","author":"Maran JJ","year":"2023","unstructured":"Maran JJ, Sharpe C, Carroll S. Paediatric MOG-antibody disease presenting with intracranial hypertension and unilateral vision loss without radiological evidence of optic neuritis. J Neuroimmunol. 2023, 378:578083. 10.1016\/j.jneuroim.2023.578083","journal-title":"J Neuroimmunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp LB","year":"2013","unstructured":"Krupp LB, Tardieu M, Amato MP, et al.. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013, 19:1261-7. 10.1177\/1352458513484547","journal-title":"Mult Scler"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813489732","article-title":"Defining encephalopathy in acute disseminated encephalomyelitis","volume":"29","author":"Fridinger SE","year":"2014","unstructured":"Fridinger SE, Alper G. Defining encephalopathy in acute disseminated encephalomyelitis. J Child Neurol. 2014, 29:751-5. 10.1177\/0883073813489732","journal-title":"J Child Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.06.017","article-title":"Acute disseminated encephalomyelitis in children: an updated review based on current diagnostic criteria","volume":"100","author":"Cole J","year":"2019","unstructured":"Cole J, Evans E, Mwangi M, Mar S. Acute disseminated encephalomyelitis in children: an updated review based on current diagnostic criteria. Pediatr Neurol. 2019, 100:26-34. 10.1016\/j.pediatrneurol.2019.06.017","journal-title":"Pediatr Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13602","article-title":"Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome","volume":"25","author":"Wong YY","year":"2018","unstructured":"Wong YY, Hacohen Y, Armangue T, et al.. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol. 2018, 25:782-6. 10.1111\/ene.13602","journal-title":"Eur J Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103216","article-title":"Treatment of MOG-IgG associated disease in paediatric patients: a systematic review","volume":"56","author":"Klein da Costa B","year":"2021","unstructured":"Klein da Costa B, Banwell BL, Sato DK. Treatment of MOG-IgG associated disease in paediatric patients: a systematic review. Mult Scler Relat Disord. 2021, 56:103216. 10.1016\/j.msard.2021.103216","journal-title":"Mult Scler Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2020.04.002","article-title":"High association of MOG-IgG antibodies in children with bilateral optic neuritis","volume":"27","author":"Wendel EM","year":"2020","unstructured":"Wendel EM, Baumann M, Barisic N, et al.. High association of MOG-IgG antibodies in children with bilateral optic neuritis. Eur J Paediatr Neurol. 2020, 27:86-93. 10.1016\/j.ejpn.2020.04.002","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/360455-paediatric-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-a-case-report-with-varied-clinical-manifestations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T09:09:00Z","timestamp":1748768940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/360455-paediatric-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-a-case-report-with-varied-clinical-manifestations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.85173","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}